Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why PJT (PJT) Stock Is Falling Today

February 03, 2026 at 11:50 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

PJT Cover Image

What Happened?

Shares of investment banking firm PJT Partners (NYSE: PJT) fell 6.9% in the morning session after the company reported mixed fourth-quarter 2025 results, where an earnings beat was overshadowed by a miss on revenue expectations.

PJT Partners posted an adjusted profit of $2.55 per share, which was 6.4% above Wall Street's consensus estimates. However, revenue for the quarter, while up 12.1% year on year to $535.2 million, fell short of analysts' projections. The stock's decline suggests that investors focused on the top-line miss, raising concerns about the company's growth trajectory despite its better-than-expected profitability.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy PJT? Access our full analysis report here, it’s free.

What Is The Market Telling Us

PJT’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 2 months ago when the stock gained 2.9% on the news that investors grew more optimistic about a potential Federal Reserve interest rate cut in December. The positive sentiment was fueled by comments from New York Fed President John Williams, a voting member of the rate-setting Federal Open Market Committee, who stated the central bank could cut rates "in the near term" without jeopardizing its inflation targets. Following his remarks, market expectations for a rate cut in December shifted significantly. According to the CME FedWatch Tool, the probability of a December rate reduction surged from a 37% chance earlier in the day to 70%. While lower rates can compress bank profit margins, investors often view them as a catalyst for broader economic activity, potentially boosting loan demand and reducing the risk of defaults.

PJT is down 6.4% since the beginning of the year, and at $158.61 per share, it is trading 17.1% below its 52-week high of $191.42 from January 2026. Investors who bought $1,000 worth of PJT’s shares 5 years ago would now be looking at an investment worth $2,180.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article